Concurrent dermatological manifestations, COVID-19 infection, and MDS/RCMD-RS: A unique case report
Main Article Content
Keywords
Myelodysplastic syndrome, COVID-19, vasculitis, dermatological manifestations, immune dysfunction
Abstract
A 24-year-old male with refractory cytopenia with multilineage dysplasia and ring sideroblasts (MDS/RCMD-RS) who developed severe dermatological manifestations concurrent with COVID-19 infection. The patient exhibited complex vasculitic and purpuric skin lesions, which were hypothesized to result from COVID-19-induced endothelitis and vasculitis, exacerbated by underlying immune dysfunction from MDS. Despite treatment with EPO therapy, cyclosporin, and supportive care, the patient's condition deteriorated rapidly, leading to fatal respiratory failure. The report underscores the interplay between hematologic malignancies, immune dysregulation, and COVID-19, highlighting the potential for exacerbated dermatological and systemic complications in such patients. This case emphasizes the need for heightened vigilance and tailored management strategies for MDS patients infected with COVID-19.
References
2. Team UoCHMCR. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood. 2016;128(14):1800–13.
3. Babushok DV, Bessler M, Olson TS. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults. Leuk Lymphoma. 2016;57(3):520–36.
4. Cada M, Segbefia CI, Klaassen R, Fernandez CV, Yanofsky RA, Wu J, et al. The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes. Haematologica. 2015;100(5):633.
5. Neumann I. Immunosuppressive and glucocorticoid therapy for the treatment of ANCA-asssociated vasculitis. Rheumatology. 2020;59(Suppl 3):iii60–7.
6. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8.
7. Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res. 2020;69(12):1181–9.
8. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, et al. Treating leukemia in the time of COVID-19. Acta Haematol. 2021;144(2):132–45.
9. Al Saleh AS, Sher T, Gertz MA. Multiple myeloma in the time of COVID-19. Acta Haematol. 2020;143(5):410–6.
10. Bilich T, Roerden M, Maringer Y, Nelde A, Heitmann JS, Dubbelaar ML, et al. Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in patients with cancer. Cancer Discov. 2021;11(8):1982–95.
11. Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022;140(3):236–52.
12. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34(6):1637–45.
13. Arruga F, Gyau BB, Iannello A, Vitale N, Vaisitti T, Deaglio S. Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions. Int J Mol Sci. 2020;21(5):1825.
14. Kim J, Lee K, Kim G, Kim S, Yang J, Li H, et al. Clinical characteristics and mortality of patients with hematologic malignancies and COVID-19: a systematic review. Eur Rev Med Pharmacol Sci. 2020;24:11926–33.
15. Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):904–13.
16. Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH research collaborative data hub. Blood Adv. 2020;4(23):5966–75.
17. Roncati L, Ligabue G, Fabbiani L, Malagoli C, Gallo G, Lusenti B, et al. Type 3 hypersensitivity in COVID-19 vasculitis. Clin Immunol. 2020;217:108487.
18. Becker RC. COVID-19-associated vasculitis and vasculopathy. J Thromb Thrombolysis. 2020;50(3):499–511.
19. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020 Jul;50(1):54-67.
20. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta. 2020 Mar;505:190-194.
21. Suchonwanit P, Leerunyakul K, Kositkuljorn C. Cutaneous manifestations in COVID-19: lessons learned from current evidence. J Am Acad Dermatol. 2020;83(1):e57–e60.
22. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020 Nov;220:1-13.
23. Suchonwanit P, Leerunyakul K, Kositkuljorn C. Diagnostic and prognostic values of cutaneous manifestations in COVID-19. Dermatol Ther. 2020;33(4):e13650.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Asaad A. Khalaf, Basrah center of hematology, Al-Sayyab teaching hospital, Basrah, Iraq.